EGFR and non-small cell lung carcinoma: For example, aberrant EGFR signaling in NSCLC cells upregulates PDL1 expression through activation of the IL6/JAK/STAT3 pathway [80], while combined STAT3 and PDL1 inhibition renders tumor cells more susceptible to cytotoxic T-cell mediated killing and delays tumor growth in mice [81].